Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling by Lamb, Rebecca et al.
Oncotarget30453www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 31
Mitochondrial mass, a new metabolic biomarker for stem-like 
cancer cells: Understanding WNT/FGF-driven anabolic signaling
Rebecca Lamb1,2,*, Gloria Bonuccelli1,2,*, Béla Ozsvári1,2, Maria Peiris-Pagès1,2, Marco 
Fiorillo1,2,3, Duncan L. Smith4, Generoso Bevilacqua5,6, Chiara Maria Mazzanti5, 
Liam A. McDonnell5, Antonio Giuseppe Naccarato6, Maybo Chiu1,2, Luke Wynne1,2, 
Ubaldo E. Martinez-Outschoorn7, Federica Sotgia1,2 and Michael P. Lisanti1,2
1 The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK
2  The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, 
UK
3 The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria, Cosenza, Italy
4 The Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK
5 FPS – The Pisa Science Foundation, Pisa, Italy
6 Department of Pathology, Pisa University Hospital, Pisa, Italy
7 The Sidney Kimmel Cancer Center, Philadelphia, PA, USA
* These authors should be considered as co-first authors
Correspondence to: Michael P. Lisanti, email: michaelp.lisanti@gmail.com
Correspondence to: Federica Sotgia, email: fsotgia@gmail.com
Keywords: mitochondria, MitoTracker, MMTV, WNT, FGF
Received: July 21, 2015 Accepted: August 22, 2015 Published: September 28, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct
Here, we developed an isogenic cell model of “stemness” to facilitate protein 
biomarker discovery in breast cancer. For this purpose, we used knowledge gained 
previously from the study of the mouse mammary tumor virus (MMTV). MMTV 
initiates mammary tumorigenesis in mice by promoter insertion adjacent to two 
main integration sites, namely Int-1 (Wnt1) and Int-2 (Fgf3), which ultimately 
activates Wnt/β-catenin signaling, driving the propagation of mammary cancer 
stem cells (CSCs). Thus, to develop a humanized model of MMTV signaling, we over-
expressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. 
We then validated that MCF7 cells over-expressing both WNT1 and FGF3 show a 3.5-
fold increase in mammosphere formation, and that conditioned media from these 
cells is also sufficient to promote stem cell activity in untransfected parental MCF7 
and T47D cells, as WNT1 and FGF3 are secreted factors. Proteomic analysis of this 
model system revealed the induction of i) EMT markers, ii) mitochondrial proteins, iii) 
glycolytic enzymes and iv) protein synthesis machinery, consistent with an anabolic 
CSC phenotype.  MitoTracker staining validated the expected WNT1/FGF3-induced 
increase in mitochondrial mass and activity, which presumably reflects increased 
mitochondrial biogenesis. Importantly, many of the proteins that were up-regulated 
by WNT/FGF-signaling in MCF7 cells, were also transcriptionally over-expressed in 
human breast cancer cells in vivo, based on the bioinformatic analysis of public gene 
expression datasets of laser-captured patient samples. As such, this isogenic cell 
model should accelerate the discovery of new biomarkers to predict clinical outcome 
in breast cancer, facilitating the development of personalized medicine. 
Finally, we used mitochondrial mass as a surrogate marker for increased 
mitochondrial biogenesis in untransfected MCF7 cells.  As predicted, metabolic 
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IntroductIon
The mouse mammary tumor virus (MMTV) is a 
saliva- and milk-transmitted retrovirus [1-5]; however, 
infected mice only develop mammary tumors in adulthood 
[4]. This long latency period makes MMTV an interesting 
virus for understanding the pathogenesis of human 
breast cancers [6]. The provirus inserts upstream of 
two key integration sites, named Int-1 and Int-2 [7-10]. 
This process of insertional mutatgenesis is thought to 
be random, but involves the positive selection of genes 
that will ultimately provide an increase in “stemness”, 
a cellular growth-advantage, or perhaps both. MMTV 
tumors are oligo-clonal, suggesting that there is some 
synergy between these two different integration sites. 
These mammary proto-oncogenes Int-1 and Int-2 have 
been identified as WNT1 and FGF3 [11-13], two secreted 
growth factors normally involved in stem cell signaling 
pathways. 
WNT1 is the first member of the WNT gene family, 
which is known to be involved in cell fate determination 
and patterning during embryogenesis [14, 15]. FGF3 is 
a member of the fibroblast growth factor family, which 
controls cell proliferation, morphogenesis and tissue 
repair [16]. Interestingly, WNT1 and FGF3 converge 
directly upon the WNT/β-catenin signaling cascade [17, 
18]. However, it remains largely unknown exactly how 
WNT1/FGF3 signaling induces mammary tumorigenesis. 
Here, we have created a humanized model of 
MMTV signaling, by over-expressing WNT1 and FGF3 
in human breast cancer cells, namely MCF7 cells, an 
ER(+) cell line. Unbiased label-free proteomic analysis of 
this model system reveals the induction of EMT markers, 
mitochondrial proteins, glycolytic enzymes and protein 
synthesis machinery, consistent with an anabolic CSC 
phenotype. The proteins that were up-regulated by WNT/
FGF-signaling in MCF7 cells, were also transcriptionally 
over-expressed in human breast cancer cells in vivo. This 
isogenic cell model should accelerate the identification 
and development of new protein biomarkers to predict 
clinical outcomes in breast cancer patients. 
Finally, we also show that mitochondrial mass 
is a new metabolic biomarker for anabolic CSCs, as 
assessed by MitoTracker vital-staining and metabolic cell 
fractionation by flow-cytometry. 
results
Generating a humanized model of MMtV 
signaling. 
During MMTV infection of mammary epithelial 
cells, genomic viral integration occurs. This ultimately 
leads to mammary tumorigenesis in mice. Mechanistically, 
fractionation of parental MCF7 cells, via MitoTracker staining, indicated that high 
mitochondrial mass is a new metabolic biomarker for the enrichment of anabolic 
CSCs, as functionally assessed by mammosphere-forming activity. This observation 
has broad implications for understanding the role of mitochondrial biogenesis in the 
propagation of stem-like cancer cells. Technically, this general metabolic approach 
could be applied to any cancer type, to identify and target the mitochondrial-rich CSC 
population.  
The implications of our work for understanding the role of mitochondrial 
metabolism in viral oncogenesis driven by random promoter insertions are also 
discussed, in the context of MMTV and ALV infections.
Figure 1: creating a humanized experimental model 
for MMtV: Focus on Wnt1 and FGF3 signaling. 
To create a humanized model of MMTV signaling, we 
recombinantly over-expressed WNT1 and FGF3 in MCF7 cells, 
an ER(+) human breast cancer cell line. WNT1 and FGF3 were 
expressed either individually or in combination, using lenti-viral 
vectors carrying two different selection markers (puromycin 
or neomycin/G418). This isogenic cell model of “stemness” 
was generated to facilitate protein biomarker discovery in 
breast cancer, via unbiased label-free proteomics. Importantly, 
over-expression of FGF3, WNT1, or WNT1/FGF3 increases 
mammosphere formation by 1.5-, 2.5- and 3.5-fold, respectively 
(See Figure 2). Thus, we focused on MCF7-WNT1/FGF3 cells 
for further validation and proteomic analysis. 
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the MMTV virus uses a promoter insertion mechanism of 
mutagenesis, to drive oncogenesis [19]. More specifically, 
the MMTV promoter inserts upstream of two main 
integration sites, namely Int-1 (Wnt1) or Int-2 (Fgf3), 
although a few other rare integration sites have been 
described [11-13, 20] (Table 1). As a consequence, the 
MMTV promoter drives the over-expression of these 
secreted stem cell associated growth factors, constitutively 
activating Wnt/β-catenin signaling [11, 21, 22]. Thus, the 
MMTV model has been instrumental for understanding 
how “amplified” or “constitutive” stem cell signaling 
directly contributes to solid tumor formation (Figure 1). 
As such, it would be beneficial to create a humanized 
non-infectious model of MMTV signaling, to drive 
the discovery of new stem cell associated biomarkers, 
for predicting clinical outcome in human breast cancer 
patients. 
Thus, in order to create a humanized model of 
MMTV signaling, we recombinantly over-expressed 
WNT1 and FGF3 in MCF7 cells, an ER(+) human breast 
cancer cell line. WNT1 and FGF3 were expressed either 
individually or in combination, using lentiviral vectors 
carrying two different selection markers (puromycin or 
neomycin/G418). For comparison purposes, empty vector 
controls (EV) were generated in parallel (Figure 1). 
Then, the various cell lines were screened for stem 
cell activity, using the mammosphere assay as a functional 
readout. Importantly, Figure 2A directly validates that 
over-expression of either WNT1 or FGF3 is sufficient 
to increase the clonal expansion of cancer stem cells. 
Interestingly, FGF3 and WNT1 significantly increased 
mammosphere formation by ~1.5-fold and ~2.5-fold, 
Figure 2: Recombinant over-expression of WNT1 and/or FGF3 in MCF7 cells significantly augments mammosphere 
formation. A) Mammosphere formation. The cell lines we generated were screened for stem cell activity, using the mammosphere assay 
as a functional readout. Note that over-expression of either WNT1 or FGF3 significantly increased mammosphere formation by ~1.5-fold 
and ~2.5-fold, respectively. However, MCF7 cells over-expressing both WNT1 and FGF3 showed the largest increase in mammosphere 
formation, by up to ~3.5-fold. Results were normalized to the three control cell lines harboring either i) EX-Neg-Lv105(puro), ii) EX-
Neg-Lv151(neo) or iii) both control vectors. P-values are as indicated. Assays were performed in triplicate and repeated three times 
independently. MFE, mammosphere forming efficiency. B) Immunoblot analysis. Recombinant over-expression of WNT1 and FGF3 in 
these transfected cell models was validated by immunoblot analysis, with specific antibody probes. Beta-actin is shown as a control for 
equal loading. 
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respectively. However, MCF7 cells over-expressing 
both WNT1 and FGF3 showed the largest increase in 
mammosphere formation, by up to ~3.5-fold (Figure 2A). 
We also validated the recombinant over-expression 
of WNT1 and FGF3 in these transfected cell models 
by immunoblot analysis, with specific antibody probes 
(Figure 2B). 
conditioned media from McF7-Wnt1/FGF3 
cells is sufficient to increase mammosphere 
formation. 
As WNT1 and FGF3 are secreted factors, it would 
be predicted that the increase in constitutive stem cell 
signaling could also act in a paracrine fashion on non-
transfected cells. To test this hypothesis, we prepared 
conditioned media from MCF7-WNT1/FGF3 cells and 
the corresponding empty vector (MCF7-EV) control cells. 
Then, we compared the ability of conditioned media 
to support mammosphere formation, in untransfected 
parental MCF7 cells. Figure 3 (Left) shows that 
conditioned media prepared from MCF7-WNT1/FGF3 
cells significantly stimulated mammosphere formation 
by ~2-fold. Importantly, virtually identical results were 
obtained with untransfected parental T47D cells, a second 
independent ER(+) breast cancer cell line (Figure 3 
(Right)). 
Proteomics analysis of MCF7-WNT1/FGF3 
cells reveals the upregulation of eMt markers, 
mitochondrial proteins, glycolytic enzymes, and 
the protein synthesis machinery. 
To better understand how WNT and FGF signaling 
drive the expansion of CSCs, we used unbiased label-free 
proteomics analysis. The proteome of MCF7-WNT1/
FGF3 cells was compared to MCF7-EV control cells. We 
restricted our analysis to protein products that were over-
expressed by >1.5-fold. Overall, our results are detailed in 
Tables 2, 3 and 4.
Remarkably, >40 nuclear-encoded mitochondrial-
related proteins were over-expressed in MCF7-WNT1/
FGF3 cells (Table 2). Many of these proteins were related 
to the TCA cycle (ACO2), oxidative phosphorylation (MT-
CO2), regenerating ATP (CKMT1/2) or mitochondrial 
biogenesis (TOMM34). In addition, MT-CO2 (a 
mitochondria-DNA encoded protein) was upregulated 
by >2.5-fold, indicative of the production of new 
mitochondria. In support of an anabolic phenotype, 
proteins related to glycolysis, the pentose phosphate 
pathway, glycogen metabolism and amino acid synthesis 
were upregulated (Table 2). 
Figure 3: conditioned media from Wnt1/FGF3 expressing McF7 cells increases mammosphere formation. Since 
WNT1 and FGF3 are secreted factors, they should act in a paracrine fashion on non-transfected cells. To test this hypothesis, we prepared 
conditioned media from MCF7-WNT1/FGF3 cells and the corresponding empty vector (MCF7-EV) control cells. Then, we compared 
the ability of this conditioned media to support mammosphere formation, in untransfected parental MCF7 cells (Left panel). Note that 
conditioned media prepared from MCF7-WNT1/FGF3 cells significantly stimulated mammosphere formation by ~2-fold. Nearly identical 
results were obtained with untransfected parental T47D cells, a second independent ER(+) breast cancer line (Right panel). Assays were 
performed in triplicate and repeated three times independently. MFE, mammosphere forming efficiency. 
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Stem-like cancer cells also undergo an epithelial-
mesenchymal transition (EMT), which promotes 
cell migration, invasion and distant metastasis [23]. 
Importantly, >45 proteins known to be associated with 
the EMT phenotype (cell migration or invasiveness) 
were upregulated in MCF7-WNT1/FGF3 cells (Table 3). 
Examples include FRS2 (FGF receptor substrate-2; >10-
fold) and β-catenin (>2-fold), which would be expected to 
further amplify WNT/FGF signaling, as these are down-
stream elements of these convergent signaling networks. 
Similarly, other signaling molecules that promote the EMT 
and cell migration were significantly upregulated, such as 
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MARCKS (>370-fold) and CDC42 (>65-fold). 
Finally, augmented protein synthesis is another 
characteristic of anabolic CSCs. Note that MCF7-WNT1/
FGF3 cells show the upregulation of >35 proteins related 
to protein synthesis (Table 4). Examples include ribosome-
related proteins (RPS and RPL), translation initiation 
factors (EIFs), peptide elongation factors (EEFs), enzymes 
for tRNA synthesis, as well as chaperones for protein 
folding (HSPs) and amino acid transporters (SLC). 
Thus, MCF7-WNT1/FGF3 cells upregulate greater 
than 140 proteins that would be consistent with an overall 
anabolic phenotype (Figure 4). 
expression of Wnt1/FGF3-related targets in 
patient-derived human breast cancer samples
To determine the possible translational significance 
of our results, we intersected our WNT-FGF proteomics 
data with human genome-wide transcriptional profiling 
data. These human clinical data were derived from 
publically available human breast cancer samples, in 
which breast cancer cells were separated by laser-capture 
microdissection from tumor stromal cells. Transcriptional 
profiles were analyzed from from N=28 human breast 
cancer patients (See the Materials & Methods section). In 
this data set, gene expression was previously determined 
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using Affymetrix U133A 2.0 GeneChips. A concise 
summary of these findings is presented in Tables 5, 6 
and 7. Overall, greater than sixty WNT1/FGF3 targets 
(related to mitochondria, glycolysis, the EMT, and protein 
synthesis) that we identified in MCF7-WNT1/FGF3 cells 
were also transcriptionally elevated in human breast 
cancer cells in vivo. These new protein targets that we 
identified in MCF7-WNT1/FGF3 cells may be important 
for developing new strategies for the diagnosis and 
treatment of breast cancer. 
McF7-Wnt1/FGF3 cells show a functional 
increase in mitochondrial mass and mitochondrial 
membrane potential
To further validate the mitochondrial phenotype of 
MCF7-WNT1/FGF3 cells, we used fluorescent probes 
to quantitate mitochondrial mass and mitochondrial 
membrane potential by FACS analysis. For this purpose, 
we used MitoTracker Deep-Red (640-nm) to measure 
mitochondrial mass and MitoTracker Orange (561-nm), 
as a measure of mitochondrial membrane potential. 
Figure 5 (Left panels) show that as compared to 
EV control MCF7 cells, MCF7 cells overexpressing 
WNT1/FGF3 show a clear shift to the right, for both 
mitochondrial mass and membrane potential. Furthermore, 
quantitation of fluorescence intensity (MFI) reveals that 
both of these mitochondrial parameters are significantly 
elevated in MCF7-WNT1/FGF3 cells (Figure 5 (Right 
panels)). 
These results suggest that increased mitochondrial 
mass and function may be important features of the 
anabolic CSC phenotype. 
High mitochondrial mass is a key determinant 
of mammosphere-forming activity in parental 
McF7 cells 
Based on our above observations with WNT1/
FGF3 signaling, we would predict that mitochondrial 
biogenesis is critical for mammosphere forming activity. 
To test this hypothesis more directly, we metabolically 
fractionated untransfected parental MCF7 cells, using 
MitoTracker Deep-Red, as a measure of mitochondrial 
mass. In this context, we chose to analyze three distinct 
metabolic phenotypic sub-groups: i) negative cells (little 
or no positive staining; mito-negative group); ii) bottom 
5% (mito-low group); and top 5% (mito-high group). Only 
live cells in each group were selected for this analysis. 
Five thousand live cells from each group were 
then seeded per well, in 6-well low attachment plates, to 
measure mammosphere-forming efficiency. Remarkably, 
Figures 6 and 7 directly show that increasing mitochondrial 
mass results in a 3.0 to 5.5-fold increase in mammosphere-
forming activity, depending on which gating parameters 
are used (singlet-gating vs. all live cells). A comparison 
with all live cells is also shown because mammary stem 
cells tend to be larger than non-stem cells (See Ref # 37 
for a discussion of this point). 
As such, the mito-negative group showed the 
least 3-D sphere-forming activity, while the mito-high 
group showed the highest 3-D sphere-forming efficiency. 
Thus, we conclude that mitochondrial mass can be 
used to enrich for stem-like cancer cells that are able to 
undergo anchorage-independent propagation, under low-
attachment conditions. 
Figure 4: The anabolic CSC phenotype: Proteomics 
analysis. Unbiased label-free proteomics analysis of MCF7-
WNT1/FGF3 cells revealed the induction of i) mitochondrial 
proteins, ii) glycolytic enzymes, iii) protein synthesis 
machinery and iv) EMT markers, consistent with an anabolic 
CSC phenotype. For specific details, see Tables 2, 3 and 4. 
Mitochondrial proteins – Greater than 40 nuclear-encoded 
mitochondrial-related proteins were over-expressed in MCF7-
WNT1/FGF3 cells. Many of these proteins were related to the 
TCA cycle (ACO2), oxidative phosphorylation (MT-CO2), 
regenerating ATP (CKMT1/2) or mitochondrial biogenesis 
(TOMM34). In addition, MT-CO2 (a mitochondrial DNA 
encoded protein) was upregulated by >2.5-fold. Glycolytic 
enzymes – More than 10 enzymes related to glycolysis, the 
pentose phosphate pathway, glycogen metabolism and amino 
acid synthesis were all upregulated in MCF7-WNT1/FGF3 
cells. Protein synthesis machinery – Over 35 proteins related to 
protein synthesis, including ribosome-related proteins, enzymes 
for tRNA synthesis, chaperones for protein folding and amino 
acid transporters, were all up upregulated in MCF7-WNT1/
FGF3 cells. EMT markers – Greater than 45 proteins known 
to be associated with the EMT phenotype were upregulated 
in MCF7-WNT1/FGF3 cells. Examples include FRS2 (FGF 
receptor substrate-2; >10-fold) and β-catenin (>2-fold). 
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dIscussIon
The mouse mammary tumor virus (MMTV) 
initiates mammary tumorigenesis in mice by promoter 
insertion adjacent to two main integration sites, namely 
Int-1 (Wnt1) and Int-2 (Fgf3), driving the propagation 
of mammary cancer stem cells [11-13, 20]. Here, we 
developed an isogenic cell model of MMTV signaling 
to facilitate protein biomarker discovery in breast 
cancer (Figure 8). More specifically, we over-expressed 
WNT1 and FGF3 in MCF7 cells, an ER(+) human 
breast cancer cell line. Importantly, MCF7 cells over-
expressing both WNT1 and FGF3 showed a 3.5-fold 
increase in mammosphere formation. Proteomic analysis 
of this model system revealed the induction of EMT 
markers, mitochondrial proteins, glycolytic enzymes and 
protein synthesis machinery, consistent with an anabolic 
phenotype. The WNT1/FGF3-induced increases in 
mitochondrial function were validated by MitoTracker 
staining. Proteins up-regulated by WNT/FGF-signaling 
in MCF7 cells, were also transcriptionally over-expressed 
in breast cancer cells in vivo, based on the bioinformatic 
analysis of public datasets of laser-captured epithelial 
tumor cells from breast cancer patients. We believe that 
this isogenic cell model will accelerate the identification 
of new protein biomarkers to predict clinical outcomes 
in breast cancer patients. Remarkably, metabolic 
fractionation of parental MCF7 cells, via MitoTracker 
staining, indicated that mitochondrial mass is a key 
determinant of mammosphere-forming activity. The mito-
negative group showed the least sphere-forming activity, 
while the mito-high group showed the highest sphere-
forming efficiency. Thus, new mitochondrial biogenesis is 
critical for the successful propagation of stem-like cancer 
cells. 
Figure 5: WNT1/FGF3 over-expressing MCF7 cells have increased mitochondrial mass and activity. We used two different 
fluorescent probes to quantitate mitochondrial mass and mitochondrial membrane potential by FACS analysis. Briefly, we employed 
MitoTracker Deep-Red (640-nm) to measure mitochondrial mass and MitoTracker Orange (561-nm), as a measure of mitochondrial 
membrane potential. Note that as compared to EV control MCF7 cells, MCF7 cells overexpressing WNT1/FGF3 show a clear shift to the 
right, for both mitochondrial mass (Lower panels) and membrane potential (Upper panels). Quantitation of fluorescence intensity (MFI) 
reveals that both of these mitochondrial parameters are significantly elevated in MCF7-WNT1/FGF3 cells. P-values are as shown. These 
results suggest that both mitochondrial mass and function may be critical features of the CSC phenotype. 
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Figure 6: Metabolic fractionation of parental MCF7 cells directly correlates with mammosphere-forming activity: 
Gating for singlet cells. We metabolically fractionated parental MCF7 cells, using MitoTracker Deep-Red, as a measure of mitochondrial 
mass. In this context, we chose to analyze three distinct metabolic phenotypic groups: i) negative cells (little or no positive staining; mito-
negative group); ii) bottom 5% (mito-low group); and top 5% (mito-high group). Only live cells in each group were selected for this 
analysis. Five thousand live cells from each group were then seeded per well, in 6-well low attachment plates, to measure mammosphere-
forming efficiency. Note that increasing mitochondrial mass results in a 3.0-fold increase in mammosphere-forming activity. Thus, the 
mito-deficient group showed the least sphere-forming activity, while the mito-high group showed the highest sphere-forming efficiency. 
Assays were performed in triplicate and repeated three times independently. The mean number of mammospheres (3-D spheroids) formed 
is shown. 
Oncotarget30463www.impactjournals.com/oncotarget
Figure 7: Metabolic fractionation of parental MCF7 cells directly correlates with mammosphere-forming activity: 
Gating for all live cells. As in Figure 6, except that FACS gating included all live cells, not only live singlets. Under these conditions, 
note that increasing mitochondrial mass results in a >5.5-fold increase in mammosphere-forming activity. Assays were performed in 
triplicate and repeated three times independently. The mean number of mammospheres (3-D spheroids) formed is shown.
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Figure 8: Anabolic csc signaling: exploiting a 
humanized model of MMTV signaling to identify the 
characteristics of anabolic cscs and achieve the goals 
of personalized medicine. A humanized isogenic model of 
MMTV-signaling was generated by co-expressing WNT1 and 
FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. 
This model was first validated using the mammosphere assay to 
measure stem cell activity and then subjected to unbiased label-
free proteomics analysis. WNT1/FGF3 protein targets identified 
in this manner were found to be transcriptionally over-expressed 
in human breast cancer cells in vivo, providing clinical validation 
of the success of our approach. Thus, we established that the 
anabolic CSC phenotype is characterized by the induction of 
EMT markers, mitochondrial proteins, glycolytic enzymes and 
protein synthesis machinery. These represent new classes of 
identified protein targets for drug discovery and the identification 
of companion diagnostics, to eradicate anabolic CSCs. 
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role of new mitochondrial biogenesis in Wnt-
signaling and asymmetric cell division in stem 
cells 
Interestingly, two previous studies have also linked 
WNT signaling to new mitochondrial biogenesis, in 
the context of skeletal muscle function and osteoblastic 
differentiation [24, 25]. For example, Yoon et al performed 
an si-RNA screen to identify novel protein targets that are 
critical for driving mitochondrial biogenesis in skeletal 
muscle cells [24]. For this purpose, they screened the 
effects of si-RNAs on C2C12 cells, representing >6,300 
genes, using a high-throughput FACS-based assay to 
measure mitochondrial function. Overall, they identified 
>150 proteins not previously recognized to be involved in 
the regulation of mitochondrial biogenesis. Bioinformatics 
analysis of this data set identified WNT/β-catenin signaling 
as a key regulator of mitochondrial biogenesis. This 
was functionally validated by using si-RNAs targeting 
β-catenin and Axin2. Moreover, treatment of C2C12 
cells with Wnt3a increased mitochondrial biogenesis 
by nearly 2-fold, which also directly correlated with a 
functional increase in oxygen consumption. Expression 
of a dominant-negative form of TCF4 blocked the effects 
of Wnt3a on mitochondrial biogenesis, indicating that 
the canonical Wnt-pathway was responsible for the 
metabolic effects of Wnt3a. Interestingly, Wnt3a mediated 
mitochondrial biogenesis also appeared to be dependent 
on down-stream effectors, such as IRS-1 and c-MYC 
[24]. Therefore, the effects of WNT/β-catenin signaling 
on mitochondrial biogenesis, may ultimately be mediated 
by the c-MYC proto-oncogene. 
Asymmetric cell division is required for the 
maintenance of the stem cell phenotype and also occurs 
in stem-like cancer cells. Recently, Weinberg and Sabatini 
assessed how mitochondria are apportioned during 
asymmetric cell division, using an immortalized model 
of mammary epithelial stem cells [26]. Interestingly, 
they observed that “newly-synthesized” mitochondria 
were concentrated in stem cells during asymmetric cell 
division, while “old” mitochondria were segregated into 
daughter cells. As such, asymmetric cell division requires 
new mitochondrial biogenesis, for the propagation the 
stem cell phenotype. These findings could mechanistically 
explain our current results, that high-mitochondrial mass 
(Figures 6 and 7) directly correlates with “stemness” and 
mammosphere-forming efficiency. 
role of mitochondrial biogenesis in anchorage-
independent growth, in transformed fibroblasts 
and cscs
In 1984, Klebe and Harriss described the use 
of a colorimetric tetrazolium dye, namely MTT, to 
distinguish between normal and transformed fibroblasts, 
when the two different immortal isogenic cell lines 
were co-cultured [27]. More specifically, they showed 
that SV40-transformed BALB/3T3 fibroblasts, which 
were undergoing anchorage-independent growth (foci-
formation), were highly MTT-positive [27]. In contrast, 
non-transformed quiescent BALB/3T3 cells were MTT-
negative, showing little or no staining [27]. As MTT-
staining has largely been attributed to mitochondrial 
oxidative function and redox activity, these results may be 
the first description of an association between anchorage-
independent growth and mitochondrial function. 
In accordance with these findings, Fisher et al., 
2011 [28] demonstrated that PGC1-α mediated activation 
of mitochondrial biogenesis is indeed required for the 
anchorage-independent growth of RAS-transformed 
fibroblasts. Moreover, recent studies with XCT790, 
a chemical inhibitor of the ERR-α/PGC1-α signaling 
network, directly showed that blocking mitochondrial 
biogenesis is sufficient to effectively prevent the 
anchorage-independent survival and propagation of 
epithelial CSCs [29]. Quantitatively similar results were 
also obtained with azithromycin and doxycycline [29, 31], 
two well-established antibiotic inhibitors of mitochondrial 
biogenesis, which target mitochondrial protein translation. 
Thus, our current results are also consistent with 
the idea that mitochondrial power somehow helps to 
energize anchorage-independent growth, which is a key 
characteristic of CSCs. 
Figure 9: Convergent role of energy metabolism in the 
pathogenesis of viral oncogenesis, driven by promoter 
insertion: A new metabolic hypothesis. We propose that 
MMTV and ALV may induce oncogenesis by a convergent 
metabolic mechanism, which relies on an anabolic CSC 
phenotype, characterized by increased mitochondrial biogenesis 
and augmented protein synthesis. See the Discussion section 
for further details. ALV, avian leukosis virus; MMTV, mouse 
mammary tumor virus. 
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Viral oncogenesis, promoter insertion and energy 
metabolism
MMTV is known to cause the development of 
mammary tumors by promoter insertion proximal to 
cellular proto-oncogenes, that when over-expressed, 
confer an oncogenic phenotype. This appears to be largely 
through the constitutive activation of WNT/β-catenin 
signaling. Here, we show that this signal transduction 
process also leads to the activation of mitochondrial 
biogenesis and an increase in the machinery necessary 
for protein synthesis, which is characteristic of an 
anabolic CSC phenotype. Previous studies have also 
shown that the ability of WNT/β-catenin signaling 
to increase mitochondrial biogenesis is dependent on 
c-MYC activation, but in the context of skeletal muscle 
cells [24]. In further support of these ideas, MMTV Int-6 
is eukaryotic translation initiation factor 3 (eIF3), which 
serves as a scaffolding protein to increase protein synthesis 
(Table 1). 
Avian leukosis virus (ALV) is another pathogen that 
induces cancer, via a promoter insertion-based mechanism 
[32, 33]. More specifically, ALV infection leads to 
proviral intergration and promoter insertion, driving the 
development of myeloid leukosis and, ultimately, frank 
leukemia in chickens. Interestingly, the most common 
ALV integration sites include c-MYC and hTERT, as well 
as other gene products related to mitochondrial biogenesis 
and function (NDUFS6 and PARK2) [34]. 
Taken together, these data imply that MMTV and 
ALV may induce oncogenesis by a convergent metabolic 
mechanism, which relies on the down-stream activation 
of c-MYC, driving increased mitochondrial biogenesis. 
Interestingly, c-MYC is also known to increase protein 
synthesis, by targeting translation initiation, as well as by 
directly increasing ribosomal biogenesis [35, 36]. As such, 
MMTV and ALV may both ultimately induce the anabolic 
CSC phenotype, via increased mitochondrial biogenesis 
and increased protein synthesis (Figure 9). In further 
support of this idea, hTERT over-expression also appears 
to be directly associated with an anabolic CSC phenotype, 
driving increased mitochondrial biogenesis and augmented 
protein synthesis [37]. Thus, this intriguing hypothesis, 
regarding the existence of a convergent metabolic 
mechanism, underlying MMTV and ALV oncogenesis, 
undoubtedly deserves further study. 
Mitochondrial dnA content and mitochondrial 
mass both increase during the transition from 
normal tissue to hyperplasia and malignancy 
Interestingly, previous studies in human endometrial 
cancer have monitored i) mt-DNA content (by RT-PCR) 
and ii) mitochondrial mass (using the enzyme activity of 
citrate synthase), during the transition to malignancy. More 
specifically, they observed that both of these parameters 
increased by up to 2 to 3 fold, when normal endometrial 
tissue was directly compared to endometrial cancer [38]. 
Similarly, they also observed that the protein expression 
levels of three mitochondrial-related transcription factors 
(TFAM, NRF1 and PGC1-alpha) were all significantly 
increased by nearly 2-fold [39]. Taken together, these 
results are all consistent with an increase in mitochondrial 
biogenesis, during the pathogenesis of tumor initiation.
Similarly, we have previously shown that markers 
of mitochondrial mass and mitochondrial activity are 
specifically localized to the basal stem cell layer in 
normal human mucosa, which co-localizes with Ki67, an 
established marker of cell proliferation [40]. In addition, 
this mitochondria-rich population of cells is dramatically 
expanded in head and neck cancers [40] and breast 
cancers [41-43]. Moreover, recombinant over-expression 
of mitochondrial-related proteins, such as PGC1-alpha/
beta, POLRMT, MitoNEET or GOLPH3, is sufficient to 
promote tumor growth, by up to 3-fold, in xenografted 
pre-clinical models of human breast cancers [44, 45]. 
Finally, mitochondrial biogenesis and mass are also 
significantly increased in hematological malignancies, 
such as in chronic lymphocytic leukemia (CLL) and acute 
myeloid leukemia (AML) [46-49]. 
This increase in mitochondrial mass also appears 
to be part of a normal developmental process, as 
mitochondrial biogenesis increases between 25 to 50 
fold, during mammalian embryogenesis, especially from 
the two-cell stage to the early blastocyst [50]. This early 
stage of embryogenesis reflects the proliferative expansion 
normal progenitor cells. Interestingly, pluripotent ES cell 
lines are derived from the inner cell mass of the blastocyst. 
conclusIons
In summary, the use of mitochondrial mass as 
a surrogate metabolic biomarker of mitochondrial 
biogenesis allows for the identification of stem-like cancer 
cells, facilitating CSC enrichment for future biomarker 
studies and aiding in the design of novel therapeutic 
interventions. In this context, MCF7 cells over-expressing 




Breast cancer cell lines (MCF7 and T47D) were 
originally purchased from the ATCC. Gibco-brand cell 
culture media (DMEM and DMEM/F12) was purchased 
from Life Technologies. Lentiviral vectors encoding 
WNT1 [EX-B0110-Lv105(puro)] and FGF3 [EX-
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A0154-Lv151(neo)] were obtained commercially from 
Genecopoeia (USA), along with appropriate empty vector 
controls [EX-Neg-Lv105(puro) and EX-Neg-Lv151(neo)]. 
Antibodies directed against FGF3 (# HPA012692, Sigma) 
and WNT1 (# ab15251, Abcam) were also obtained 
commercially. MitoTracker probes (Deep-Red and 
Orange) were purchased from Molecular Probes, via Life 
Technologies. 
McF7 cell viral transduction and antibiotic 
selection
Lentiviral particles harboring human WNT1 [EX-
B0110-Lv105(puro)] or human FGF3 [EX-A0154-
Lv151(neo)] were prepared and used to stably transduce 
MCF7 cells, according to the manufacturer’s protocol. 
After 24 hours, media containing the virus was removed 
and replaced with standard media. Cells were then 
selected with puromycin (2 μg/ml) or G418 (2 mg/ml), 
for up to 10 days. MCF7 cells harboring the empty vector 
alone controls were generated at the same time in parallel. 
MCF7-WNT1/FGF3 cells were generated by serial 
transduction with both WNT1 and FGF3 lentiviral vectors. 
Wnt1 and FGF3 immunoblotting
Transduced MCF7 cells were seeded in 10 cm 
dishes for 72 hrs. Then, cells were lysed in RIPA buffer 
(Sigma), containing proteinase inhibitors (Roche) and 
kept at 4°C for 30 minutes. Lysates were collected by 
centrifugation for 10 minutes at 10,000 x g, and protein 
concentration were determined using the BCA protein 
assay kit (Pierce). Samples were diluted into SDS-PAGE 
sample buffer and were boiled for 5 minutes before 
being separated by SDS-PAGE, using a 4-15% gradient 
Mini-PROTEAN TGX Gel (Biorad). Samples were then 
transferred onto a nitrocellulose membrane (Biorad), 
blocked in 5% milk in TBS-Tween 20 (Sigma) and 
probed with antibodies directed against WNT1 or FGF3 
and β-actin (Santa Cruz Biotechnology, #sc-1616), using 
a secondary antibody at a dilution of 1 to 5000. Bound 
antibodies were detected using the Supersignal West 
Pico Chemiluminiscent substrate (ThermoScientific). 
Alternatively, in the laboratory, blots were also routinely 
processed with a blocking solution containing BSA, as a 
blocking agent. Similarly, other comparable antibodies 
directed against β-actin were used, but were obtained from 
different commercial sources, such as Sigma.
Assessment of mammosphere forming activity
Mammosphere formation was carried out, essentially 
as described previously by Clarke and colleagues, without 
any significant modifications [51]. MCF7 cells were plated 
at a density of 500 cells/cm2 in mammosphere medium in 
culture dishes coated with poly-HEMA (Sigma, #P3932). 
After 5 days, 3D spheroids with a diameter greater than 
50 µm were counted using a microscope, fitted with a 
graticule eye-piece, and the percentage of cells which 
formed spheroids was calculated and normalized to one 
(1 = 100 % MSE; mammosphere forming efficiency). 
Mammosphere assays were performed in triplicate and 
repeated three times independently.
conditioned media experiments
One million MCF7 cells transfected with WNT1/
FGF3 or empty vector alone controls were plated for 24 
hours in DMEM (10% FCS). Cells were then washed 
in PBS, the subsequently cultured for 72 hours in 10 ml 
of DMEM/F12 phenol-red free media (mammosphere 
media). Media was then collected and cells were removed 
by centrifugation at 1800 rpm for 10 minutes. Conditioned 
media was then added directly to mammosphere assays 
of parental untransfected breast cancer cell lines (MCF7 
and T47D) in a ratio of 1:1 with fresh mammosphere 
formation media.
Unbiased label-free proteomics analysis
Proteomics analysis was carried out essentially as 
we previously described, with minor modifications [52, 
53]. Statistical analyses were performed using ANOVA 
and only fold-changes in proteins with a p-value less than 
0.05 were considered significant. Unbiased proteomics and 
the statistical analysis of the results were performed by the 
Biological Mass Spectrometry Core Facility, at the Cancer 
Research UK Manchester Institute, under the supervision 
of Dr. Duncan L. Smith. 
Bioinformatics analysis with publically available 
human breast cancer clinical data
To determine the possible translational significance 
of our proteomics analysis, we intersected our MCF-
based WNT/FGF proteomics data with human genome-
wide transcriptional profiling data. These human clinical 
data were derived from publically available human 
breast cancer samples, in which breast cancer cells were 
separated by laser-capture microdissection from tumor 
stromal cells. Transcriptional profiles were analyzed from 
N=28 human breast cancer patients [54]. 
Analysis of mitochondrial mass and membrane 
potential
To measure mitochondrial activity, cells were 
stained with MitoTracker Orange (#M7510, Invitrogen), 
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whose accumulation in mitochondria is dependent upon 
membrane potential. To measure mitochondrial mass, 
cells were stained with MitoTracker Deep Red (#M22426, 
Invitrogen), localizing to mitochondria regardless of 
mitochondrial membrane potential. Cells were incubated 
with pre-warmed MitoTracker staining solution (diluted 
in PBS/CM to a final concentration of 10 nM) for 30-60 
min at 37 °C. All subsequent steps were performed in 
the dark. Cells were washed in PBS, harvested, and re-
suspended in 300 μL of PBS. Cells were then analyzed 
by flow cytometry. Data analysis was performed using 
FlowJo software.
Metabolic fractionation of parental McF7 cells 
using Mitotracker
Using MitoTracker Deep-Red staining as a marker 
of mitochondrial mass, we metabolically fractionated 
parental MCF7 cells, using FACS analysis and cell 
collection. In these experiments, we analyzed three 
different metabolic sub-groups: i) negative cells (little or 
no positive staining; mito-negative group); ii) bottom 5% 
(mito-low group); and top 5% (mito-high group). Only 
live cells in each group were selected for this analysis. 
Five thousand live cells from each group (performed 
in triplicate) were then seeded per well, in 6-well low 
attachment plates, to measure mammosphere-forming 
efficiency. Gating for cell size was varied to take into 
account the observation that stem-like mammary cells 
may be physically larger than “bulk” cancer cells, as was 
previously suggested. 
This method is a further refinement of a protocol 
used by Farnie, Sotgia and Lisanti, in a companion study 
published in parallel [55]. Importantly, very similar 
results were obtained here, indicating that the method is 
operator independent. For example, see Figure 4 (Panel 
A) in Farnie et al., 2015, for comparison purposes [55]; 
however, in this companion paper, the mito-negative group 
was not analyzed. 
Statistical analyses
Statistical significance was determined using the 
Student’s t-test or ANOVA, where appropriate. Values of 
less than 0.05 were considered significant. Data in figures 
are shown as the mean ± SEM, unless stated otherwise.
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